Drug profile · INN
somatrogon
NGENLA
somatrogon (NGENLA) is a growth hormone receptor agonist. Associated with Pfizer Australia Pty Ltd.
EMA: approved TGA: approved Systemic hormonal preparations (H01) H01AC08
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — somatrogon
- Class
- Systemic hormonal preparations (H01)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
somatrogon (NGENLA) is a growth hormone receptor agonist. Associated with Pfizer Australia Pty Ltd.
Key facts
INN somatrogon
Brand NGENLA
Mechanism Growth hormone receptor agonist
Target Growth hormone receptor
Therapeutic class Systemic hormonal preparations (H01)
ATC code H01AC08
Originator Pfizer Australia Pty Ltd
Mechanism of action
Growth hormone receptor agonist
Primary target: Growth hormone receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Related & competitor drugs
Frequently asked questions
What is somatrogon?
somatrogon (NGENLA) is a growth hormone receptor agonist. Associated with Pfizer Australia Pty Ltd.
What is the brand name for somatrogon?
NGENLA is a marketed brand name for somatrogon. Check FDA Drugs@FDA for the current US label holder and prescribing information.